Endolytix is a biotechnology company developing targeted therapies for infectious diseases. The company focuses on innovative biologic approaches to selectively eliminate pathogenic bacteria while preserving beneficial microbiota. Leveraging proprietary technologies and advanced research capabilities, Endolytix aims to address unmet medical needs in bacterial infections, delivering safe and effective treatments for improved patient outcomes.